This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Healthcare ETF (IHF) Tops in October: 5 Best Stocks
by Sweta Killa
Inside the best performing stocks of the top ETF of October.
NeoGenomics (NEO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 16.67% and 5.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Meets Q2 Earnings Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NeoGenomics (NEO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 40.00% and 9.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Ready Capital, Gladstone, NeoGenomics, Digi and Paramount
by Zacks Equity Research
Zacks.com featured highlights include: Ready Capital, Gladstone, NeoGenomics, Digi and Paramount
NeoGenomics (NEO) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Breakout Stocks for Stellar Returns
by Swarup Gupta
This method involves zeroing in on stocks whose prices vary within a narrow band.
Is NeoGenomics (NEO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NEO) Outperforming Other Medical Stocks This Year?
Is NeoGenomics (NEO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NEO) Outperforming Other Medical Stocks This Year?
NeoGenomics (NEO) Stock Moves -1.04%: What You Should Know
by Zacks Equity Research
NeoGenomics (NEO) closed the most recent trading day at $11.46, moving -1.04% from the previous trading session.
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
5 Healthcare Bets to Stay in Investors Good Books Next Year
by Zacks Equity Research
Based on a few key factors, we zero in on five stocks that show promise to retain the bull run in 2019.
QIAGEN Partners With Novartis to Expand CDx Tests Suite
by Zacks Equity Research
QIAGEN (QGEN) progresses well with the strategy to expand through strategic collaborations. The latest tie up will boost the company's companion diagnostic portfolio.
Is NeoGenomics (NEO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NEO) Outperforming Other Medical Stocks This Year?
QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach
by Zacks Equity Research
The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.
New Strong Buy Stocks for November 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Eyenovia Initiates Phase III Study for Mydriasis Candidate
by Zacks Equity Research
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.
New Strong Buy Stocks for November 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Top Ranked Momentum Stocks to Buy for November 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th
NeoGenomics (NEO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 66.67% and 4.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EBS vs. NEO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EBS vs. NEO: Which Stock Is the Better Value Option?